Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase ...
2018年1月29日 - 11:00PM
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of novel
therapeutics that modulate the human gut microbiome to treat
gastrointestinal diseases, today announced the appointment of Diane
J. Plotkin, Ph.D., as Vice President of Clinical Development.
Dr. Plotkin joins Ritter Pharmaceuticals with
nearly thirty years of experience in strategic, global clinical
pharmaceutical research involving all phases of drug development.
During her career, she has contributed to over fifteen Phase 3
clinical trials and multiple drug development programs leading to
successful marketing approvals in both large-scale pharmaceutical
and biotechnology companies. Dr. Plotkin was recently Senior
Director of Worldwide Clinical Development for ActivX Biosciences,
Inc., a subsidiary of Kyorin Pharmaceuticals Co., Ltd., where she
established and led the clinical development department to evaluate
drugs for metabolic disorders from 2008 to 2014. Prior to ActivX,
she spent the majority of her career at Merck Research Laboratories
where she held positions of increasing responsibility serving most
recently as Associate Director within the Department of Clinical
Endocrinology and Metabolism, and Department of Cardiovascular and
Atherosclerosis Clinical Research. Dr. Plotkin received her B.A.
Magna Cum Laude in biology from Wheaton College, earned her Ph.D.
in biology from the University of Chicago, and completed her
post-doctoral work at Yale University.
Dr. Plotkin will oversee the Company’s clinical development
program of RP-G28 to treat patients with lactose intolerance,
including the Company’s launch of its first pivotal Phase 3
clinical trial of approximately 500 subjects. Enrollment is
expected to start early this summer.
“As a person who suffers from severe lactose intolerance, I am
both motivated personally and enthusiastic professionally to join
the talented team at Ritter Pharmaceuticals at a pivotal moment in
the Company’s pursuit of developing the first FDA-approved
treatment for lactose intolerance,” commented Dr. Plotkin. “A first
in class drug in a new therapeutic area presents a unique
opportunity to make real positive impact on public health.”
“Dr. Plotkin has extensive experience and knowledge of clinical
trials and the FDA approval process,” added Andrew J. Ritter,
co-founder and president of Ritter Pharmaceuticals, Inc. “Following
our End-of-Phase 2 meeting, we have a clear path forward into our
Phase 3 program from the FDA. We look forward to having Dr. Plotkin
actively lead our clinical team as we are committed to ensuring
that the clinical development of RP-G28 is executed safely with
scientific rigor and high-quality pharmaceutical execution.”
About Ritter
Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the human gut microbiome to treat
gastrointestinal diseases. The Company’s lead product, RP-G28, has
the potential to become the first FDA-approved treatment for
lactose intolerance, a condition that affects millions worldwide.
RP-G28 has been studied in Phase 2 trials and is now in Phase 3
clinical development. The Company is further exploring the
functionality and discovering the therapeutic potential gut
microbiome changes may have on treating/preventing a variety of
conditions including: gastrointestinal diseases, immuno-oncology,
metabolic, and liver disease.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements refer to
future plans and expectations, including statements regarding the
timing of our first Phase 3 pivotal clinical trial. Management
believes that these forward-looking statements are reasonable as
and when made. However, such statements involve a number of
known and unknown risks and uncertainties that could cause the
Company’s future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Factors
that could affect the Company’s actual results are included in the
Company’s SEC filings, including the Company’s most recent reports
on Form 10-K and 10-Q filed with the SEC. These forward-looking
statements are made only as of the date hereof, and, except as
required by law, the Company undertakes no obligation to update or
revise its forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts
Investor Contact:
Jeffrey Benjamin
310-203-1000
jeffrey@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024